Logo

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEL) Induction Study for the Treatment of Crohn's Disease

Share this
AbbVie Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEL) Induction Study for the Treatment of Crohn's Disease

AbbVie Reports Results of Rinvoq (upadacitinib) in P-III (U-EXCEL) Induction Study for the Treatment of Crohn's Disease

Shots:

  • The P-III (U-EXCEL) induction study to evaluate upadacitinib (45mg) in adults with mod. to sev. CD who had inadequately responded or intolerant to one or more conventional & biological therapies
  • The trial met its 1EPs & 2EPs i.e., patients achieved clinical remission @12wks. (49% vs 29%), clinical remission (51% vs 22%), endoscopic response (46% vs 13%), steroid-free clinical remission, symptom improvement & the safety profile was consistent with the safety profile observed in previous studies with no new safety risks, SAEs (6.9% vs 6.8%)
  • RINVOQ (15/30mg) is a selective & reversible JAK inhibitor & is approved in the US & EU for AD while 15 mg is also approved in the US & EU for RA

 Ref: PR Newswire | Image: AbbVie

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions